HIV-infected progressors and long-term non-progressors differ in their capacity to respond to an A-class CpG oligodeoxynucleotide

We used an A-class CpG oligodeoxynucleotide to explore innate immunity in HIV infection and observed that natural killer cells from progressors showed a markedly lower IFN-gamma production in response to the oligonuclotide as compared with long-term non-progressing subjects and healthy HIV-negative...

Full description

Saved in:
Bibliographic Details
Published inAIDS (London) Vol. 19; no. 16; pp. 1924 - 1925
Main Authors Saez, Raquel, Echaniz, Pilar, de Juan, Maria Dolores, Iribarren, José Antonio, Cuadrado, Emilio
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 04.11.2005
Subjects
Biological and medical sciences
Case-Control Studies
Disease Progression
Follow-Up Studies
HIV Infections - immunology
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Interferon-gamma - biosynthesis
Killer Cells, Natural - metabolism
Medical sciences
Oligodeoxyribonucleotides - pharmacology
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Infection
Immunopathology
Viral disease
AIDS
Asymptomatic
Immune deficiency
Long term
Online AccessGet full text
ISSN0269-9370
DOI10.1097/01.aids.0000191229.52385.5f

Cover

More Information
Summary:We used an A-class CpG oligodeoxynucleotide to explore innate immunity in HIV infection and observed that natural killer cells from progressors showed a markedly lower IFN-gamma production in response to the oligonuclotide as compared with long-term non-progressing subjects and healthy HIV-negative individuals. This functional defect was found in patients who showed a long immunological reduction and in those who had had a recent reduction in their CD4 cell counts.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0269-9370
DOI:10.1097/01.aids.0000191229.52385.5f